Design-Elememt

PDF

vfa/vfa bio Position Paper Nanobiotechnology / Nanomedicine


By international comparison, Germany holds a strong position in the field of nanotechnology, a cross-sectional technology, implemented in many different fields. Nanobiotechnology, or the application in areas of medicine, pharmacy and life sciences to be precise, has the potential of opening up new or improved/earlier diagnostic or therapeutic opportunities for diseases that were previously insufficiently curable or completely incurable.
Download

PDF

US publication contains incorrect calculation of the development costs for cancer drugs


New analysis of development costs for cancer drugs by US medics is flawed. The sample is not representative. Essential cost drivers are not included.
Download

PDF

Pharma Dialog – The work starts now (Press Release 12. April 2016)


Today, the German government submitted its report on the Pharma Dialog. The agencies involved were the Ministry of Health, the Ministry for Education and Research, and the Ministry for Economic Affairs and Energy.
Download

PDF

vfa/vfa bio Position Paper "Biosimilars"


vfa and vfa bio, representing biopharmaceutical companies with and without biosimilar activities, are committed to competition between biopharmaceutical therapy options so as to improve health care for patients. We advocate for general conditions for the quality-assured use of bio-pharmaceuticals - original products and biosimilars:
Download

PDF

vfa/vfa bio Position Paper Orphan Drugs


Given the large number of orphan diseases and because of the huge medical need for new therapeutic options especially for people with rare diseases, there is still a very great deal of work to be done in this area. vfa and vfa bio are strongly committed to rigorously promoting the development of new therapies for orphan diseases throughout the value chain.
Download

PDF

Position paper “Cost development for clinical trials in Germany”


Currently, Germany is well prepared in principle and is internationally competitive as a location for conducting clinical trials. This is demonstrated by its No. 1 rank in Europe and No. 2 worldwide (behind the United States) in clinical trials. However,...
Download

Statement for the German Federal Ministry of Health: On the experience of the research-based pharmaceutical companies with the Act on the Restructuring of the Pharmaceutical Market (AMNOG)


(Written inquiry of the German Federal Ministry of Health to the associations on February 14, 2013)
read on

vfa Press Release 003/2014

"Trial and error” at the patients’ expense


"Trial and error” at the patients’ expense
(© vfa / H. Klappert)
The German Bundestag is implementing a number of pharmaceutical policy changes within the scope of the 14th law amending Book V of the German Social Code.
read on

vfa Press Release 033/2012 - Monday, November 19, 2012

Great potential!


The service sector is important, especially for the state of Berlin. Nonetheless, Berlin needs industry, and Berlin has industry. Added value and, as a result, jobs, high taxes and profits come from industry. In this respect, the pharmaceutical industry has a special significance for Berlin. It is one of the city’s few industrial growth centers and a growth engine within the region’s important health care sector.
read on

vfa position on endpoints for oncological therapies


Due to the severity of oncological diseases, pivotal studies are subject to special methodological characteristics that must be taken into account during the selection of endpoints and the interpretation of the results.
read on

vfa Position Paper

"Qualified Person (QP)"


Over the past few years, the requirements for pharmaceutical production and control have fundamentally changed. For example, based on the implementation of the ICH Q8, Q9 and Q10 guidelines, more importance is assigned to process control and quality assurance. As a result, the final quality only serves the purpose of formal confirmation. Consequently, these changes also entail modifications in the requirements profile for the qualified person pursuant to Section 14 of the Medicinal Products Act/Art. 48 of Directive 2011/83/EC (hereafter referred to as Qualified Person/QP).
read on

vfa Press Release 006/2011 - Thursday, March 17, 2011

Birgit Fischer to be Director General of the vfa


Berlin (vfa). Effective May 1, 2011, Birgit Fischer will become Director General of the German Association of Research-Based Pharmaceutical Companies (vfa). At present, Ms. Fischer is Chair of the Management Board of Barmer GEK, Germany’s largest statutory health insurance fund.
read on

The Pharmaceutical Industry in Germany

Germany: The Perfect Location for Research, Production and Sales - a publication by GERMANY TRADE & INVEST and vfa
Brochure Download